Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Payables (2023 - 2026)

Beta Bionics' Payables history spans 4 years, with the latest figure at $2.3 million for Q1 2026.

  • On a quarterly basis, Payables fell 32.89% to $2.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.3 million, a 32.89% decrease, with the full-year FY2025 number at $5.0 million, up 75.25% from a year prior.
  • Payables hit $2.3 million in Q1 2026 for Beta Bionics, down from $5.0 million in the prior quarter.
  • Over the last five years, Payables for BBNX hit a ceiling of $5.0 million in Q4 2025 and a floor of $1.2 million in Q4 2023.
  • Historically, Payables has averaged $3.2 million across 4 years, with a median of $3.4 million in 2025.
  • Biggest five-year swings in Payables: soared 144.6% in 2024 and later plummeted 32.89% in 2026.
  • Tracing BBNX's Payables over 4 years: stood at $1.2 million in 2023, then surged by 144.6% to $2.9 million in 2024, then soared by 75.25% to $5.0 million in 2025, then crashed by 53.62% to $2.3 million in 2026.
  • Business Quant data shows Payables for BBNX at $2.3 million in Q1 2026, $5.0 million in Q4 2025, and $4.5 million in Q3 2025.